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Abstract
Background: The development of COPD in subjects with alpha-1 antitrypsin (AAT) deficiency is likely to be
influenced by modifier genes. Genome-wide association studies and integrative genomics approaches in COPD
have demonstrated significant associations with SNPs in the chromosome 15q region that includes CHRNA3
(cholinergic nicotine receptor alpha3) and IREB2 (iron regulatory binding protein 2).
We investigated whether SNPs in the chromosome 15q region would be modifiers for lung function and COPD in
AAT deficiency.
Methods: The current analysis included 378 PIZZ subjects in the AAT Genetic Modifiers Study and a replication
cohort of 458 subjects from the UK AAT Deficiency National Registry. Nine SNPs in LOC123688, CHRNA3 and IREB2
were selected for genotyping. FEV1 percent of predicted and FEV1/FVC ratio were analyzed as quantitative
phenotypes. Family-based association analysis was performed in the AAT Genetic Modifiers Study. In the replication
set, general linear models were used for quantitative phenotypes and logistic regression models were used for the
presence/absence of emphysema or COPD.
Results: Three SNPs (rs2568494 in IREB2, rs8034191 in LOC123688, and rs1051730 in CHRNA3) were associated with
pre-bronchodilator FEV1 percent of predicted in the AAT Genetic Modifiers Study. Two SNPs (rs2568494 and
rs1051730) were associated with the post-bronchodilator FEV1 percent of predicted and pre-bronchodilator FEV1/FVC
ratio; SNP-by-gender interactions were observed. In the UK National Registry dataset, rs2568494 was significantly
associated with emphysema in the male subgroup; significant SNP-by-smoking interactions were observed.
Conclusions: IREB2 and CHRNA3 are potential genetic modifiers of COPD phenotypes in individuals with severe
AAT deficiency and may be sex-specific in their impact.
Keywords: CHRNA3, Chronic obstructive pulmonary disease, Genetic association analysis, Genetic modifiers, IREB2
Background
Chronic obstructive pulmonary disease (COPD) is a
complex disease characterized by persistent airflow lim-
itation. COPD risk likely results from the cumulative
effect of environmental factors (especially cigarette
smoking), genetic factors, and gene-by-environment
interactions [1]. Alpha-1 antitrypsin (AAT) deficiency,
typically caused by homozygosity for the Z allele at the
AAT gene (SERPINA1), is a proven genetic cause of
COPD. However, the development of COPD and
emphysema in subjects with AAT deficiency is highly
variable and is likely influenced by modifier genes and
environmental factors [2-4].
Spirometric measurements of pulmonary function are
widely used phenotypes in evaluating AAT deficient
subjects and monitoring lung function decline [5]; CT
scan assessments for emphysema have been used as
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additional intermediate phenotypes of COPD to over-
come some of the heterogeneity inherent in spirometric
classifications alone. Familial aggregation studies of pul-
monary function have suggested additional modifier
genes in AAT deficiency subjects [6,7]. A few potential
AAT candidate modifier genes, including NOS3 [8],
GSTP1 [9], TNF [10], and IL10 [11], have been reported
so far, but these results have not been consistently
replicated.
Genome-wide association (GWA) studies have revolu-
tionized the identification of susceptibility genes for com-
plex diseases. Three recent GWA studies showed that
SNPs in a region of chromosome 15q25 were signifi-
cantly associated with lung cancer; several nicotinic acet-
ylcholine receptor genes, including CHRNA3 and
LOC123688, are located in this region [12-14]. A gen-
ome-wide association (GWA) study in COPD also
showed significant associations between COPD suscept-
ibility and SNPs in this region [15]. This region was also
associated with airflow obstruction and emphysema
[16,17]. Interestingly, in addition to nicotinic acetylcho-
line receptor genes, this region also includes IREB2 (iron
regulatory binding protein 2). IREB2 was identified as a
potential COPD susceptibility gene using an integrative
genomics approach with gene expression analysis of lung
tissue samples followed by genetic association analysis
[18]. We hypothesized that SNPs in this chromosome
15q region may be modifiers of intermediate phenotypes
of COPD in subjects with severe AAT deficiency.
Methods
Study subjects
The current analysis included 378 subjects with severe
AAT deficiency (protease inhibitor [PI] ZZ) from 167
families in the AAT Genetic Modifiers Study. Ascertain-
ment of eligible sibling pairs was based on homozygosity
for the Z allele at the SERPINA1 locus as previously
described [19]. Pre- and post-bronchodilator study spiro-
metry testing was performed according to American
Thoracic Society (ATS) standards as described previously
[19]. Percent predicted values for FEV1 were calculated
using equations of Crapo and colleagues for Caucasian
subjects [20]. The FEV1/FVC ratio was analyzed using
unadjusted values. Pack-years of cigarette smoking were
calculated by multiplying the number of years smoked by
the average number of daily cigarettes smoked, divided
by 20. All participants provided written informed con-
sent, and the study protocol was approved by individual
Institutional Review Boards at each of the participating
clinical centers (Partners IRB, 2001P001237). 458 unre-
lated Caucasian subjects from the UK AATD National
Registry were also genotyped. Approval for the study was
given by the local ethics committee. All patients had a
serum alpha-1 antitrypsin (AAT) level of < 11 μM and PI
ZZ genotype confirmed by allele-specific PCR (Heredilab,
Salt Lake City, Utah, USA). None of the UK subjects had
ever received AAT augmentation therapy. A full clinical
assessment including smoke exposure, presence of
chronic bronchitis (defined as a productive cough for at
least 3 months in at least 2 consecutive years [21]), lung
function testing and high resolution CT scanning of the
chest was undertaken, as described previously [22]. The
presence of emphysema was determined by the appear-
ance of the scan and density mask analysis of slices at the
level of the aortic arch (representing the upper zone) and
the inferior pulmonary vein (representing the lower
zone) using a threshold of -910 Hounsfield Units (HU).
This HU threshold has been validated against physiologi-
cal measures in AATD [22]. Patients whose voxel index
exceeded values seen in normal subjects in either zone
[23] were classified as having emphysema.
Genotyping
Two SNPs (rs8034191 and rs1051730) in chromosome
15 were selected from the previous GWA in COPD
[15]. Additionally, 7 SNPs in IREB2 were selected using
pairwise linkage disequilibrium (LD)-tagging in Tagger
with a minimum minor allele frequency of 0.05 and r2-
threshold of 0.8 [24]. SNPs were genotyped using Seque-
nom (San Diego, CA) assays in the AAT Genetic Modi-
fiers Study. All family data were evaluated for familial
inconsistencies using the PEDCHECK program [25].
In UK AATD National Registry study, genotyping was
carried out using TaqMan® technologies (Applied Bio-
systems, UK) on an ABI7900 HT for 3 SNPs associated
in the test dataset (rs2568494, IREB2; rs8034191,
LOC123688; rs1051730, CHRNA3). All genotyping
assays were pre-validated by the suppliers, and all plates
included appropriate negative controls.
Statistical analysis
Hardy-Weinberg equilibrium was assessed using good-
ness of fit tests. Pre- and post-bronchodilator FEV1 per-
cent of predicted and pre- and post-bronchodilator
FEV1/FVC ratio were analyzed as quantitative pheno-
types. Family-based association analysis was performed
using PBAT software version 3.6 [26] assuming additive
genetic models, adjusting for pack-years and pack-years2
of cigarette smoking, under the null hypothesis of no
linkage and no association in the AAT Genetic Modi-
fiers Study. In addition to the overall model, we evalu-
ated gender-stratified models and models that included
a SNP-by-smoking or a SNP-by-gender interaction term.
Haplotype analysis was performed using 8, 4, 3, 2 SNP
adjacent sliding windows in PBAT.
In the UK AATD National Registry study, data were
analyzed using SPSS (version 16, Chicago: SPSS Inc).
Quantitative genetic association analysis was carried out
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for FEV1 and FEV1/FVC using general linear models,
adjusting for age, gender and smoke exposure (as pack-
years and pack-years2). Logistic regression models were
used for the presence of emphysema or COPD (defined
as post bronchodilator FEV1/FVC < 0.7) accounting for
covariates as before. Additive models were assumed for
all SNPs. Gender stratification and SNP-by-gender and
SNP-by-smoking interaction analyses were also carried
out, as in the test dataset.
Results
Demographic characteristics
The mean age of subjects was 52.2 years, and mean post-
bronchodilator FEV1 was 65.9% predicted in the AAT
Genetic Modifiers Study and 50.3 years and 53.8% pre-
dicted in the UK AATD National Registry, respectively
(Table 1). Male subjects were 46% in AAT Genetic Modi-
fiers Study and 59% in UK AATD National Registry,
respectively. Three hundred and sixty-six subjects
(79.8%) had emphysema in UK AATD National Registry.
Association analysis
There were no deviations from Hardy Weinberg equili-
brium for any of the genotyped SNPs.
In the AAT Genetic Modifiers Study, three SNPs
(rs2568494 in IREB2, rs8034191 in LOC123688, and
rs1051730 in CHRNA3) were associated with pre-bronch-
odilator FEV1 percent of predicted (p < 0.05 Table 2 Fig-
ure 1). Two SNPs (rs2568494 and rs1051730) were
associated with post-bronchodilator FEV1 percent of pre-
dicted and pre-bronchodilator FEV1/FVC ratio. One SNP
(rs1051730) was associated with post-bronchodilator
FEV1/FVC ratio (Table 2). Linkage disequilibrium
(assessed with r2) between rs8034191 and the 1051730
was 0.9 (Figure 2). There was significant association only
with a 2 SNP haplotype including rs8034191 and
rs1051730 with pre- bronchodilator FEV1/FVC ratio (glo-
bal test statistic; p = 0.05) using PBAT.
Interactions with cigarette smoking
There was no association between any of the genotyped
SNPs and pack-years of smoking as the outcome in the
AAT Genetic Modifiers Study. Inclusion of a SNP-by-
pack-years interaction term for the lung function pheno-
types showed significant interaction of rs1051730 with
pack-years of smoking for the pre- bronchodilator
FEV1/FVC ratio (main effect; p = 0.02, interaction effect;
p = 0.04). There was no significant association with lung
function phenotypes when the study population was
stratified into groups of ever-smokers (n = 233) and
never-smokers (n = 145) although this stratified analysis
reduced the number of informative families
considerably.
Genotype-by-gender interactions and gender
stratification
SNP-by-gender interaction analysis showed significant
interaction of rs2568494, rs8034191, and rs1051730 with
gender in models for the post-bronchodilator FEV1/FVC
ratio (main effect; p = 0.04, 0.04, 0.02, interaction effect;
p = 0.02, 0.008, 0.004, respectively). Additionally,
rs1051730 showed significant interaction in models for
pre and post-bronchodilator FEV1 and pre-bronchodila-
tor FEV1/FVC ratio (main effect; p = 0.04, 0.04, 0.08,
interaction effect; p = 0.04, 0.02, 0.04, respectively).
In the stratified analysis, for the male subgroup, the p
values were similar to the whole cohort results, with
rs8034191 showing significant association with pre- and
post-bronchodilator FEV1 percent of predicted and
post-bronchodilator FEV1/FVC ratio (Table 3). However,
in the female subgroup, there was no significant associa-
tion with lung function phenotypes.
Replication analysis
In the initial analyses in the whole UK dataset, no signif-
icant associations with quantitative phenotypes including
FEV1 and FEV1/FVC and qualitative presence of emphy-
sema and COPD were observed (all p > 0.05). Gender
interaction was apparent for rs2568494 with both
COPD and emphysema (main effect p = 0.10, interac-
tion p = 0.04 and 0.06, 0.03 respectively). No other sta-
tistically significant gender interactions were observed.
In the sex-stratified models, evidence of association for
SNPs in IREB2 and LOC123688 was observed. A trend
Table 1 Baseline characteristics for PI ZZ individuals in the AAT Genetic Modifiers Study and the UK AATD National
Registry
Characteristics AAT Genetic Modifiers Study
(n = 378)
UK national registry for AATD
(n = 458)
p value
Age, years 52.2 ± 9.7 50.3 ± 10.4 0.01
Male sex (%) 173 (46%) 252 (55%) < 0.0001
FEV1% predicted 65.9 ± 33.5 53.8 ± 32.2 0.0001
FEV1/FVC 0.551 ± 0.207 0.445 ± 0.194 < 0.0001
Pack-years for ever smokers 18.2 ± 14.5 15.9 ± 14.7 < 0.0001
Data are presented as means (± S.D.) in the AAT Genetic Modifiers Study and the UK national registry for AATD, unless otherwise noted
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was observed for association of rs8034191 and
rs2568494 with COPD in the male subgroup, the risk
alleles being C and A respectively (both p = 0.09). The
SNP rs2568494 in IREB2 was significantly associated
with emphysema in the male subgroup, the A allele con-
ferring an odds ratio and 95% confidence interval (OR
and 95% CI) of disease of 2.67 (1.10-6.51, p = 0.03). No
association was seen with rs1051730 with emphysema.
With addition of a SNP-by-smoking interaction term,
both rs8034191 and rs2568494 were associated with
COPD in the male subgroup (main effect, p = 0.03;
interaction effect, p = 0.02; and main effect, p = 0.04;
interaction effect, p = 0.003, respectively). Similar asso-
ciations with emphysema were seen for rs2568494 (p =
0.03 and 0.02 respectively). Positive findings in the two
datasets are summarized in Table 4.
Discussion
SNPs in the chromosome 15 CHRNA3/CHRNA5/
LOC123688/IREB2 region have been shown to have
associations with lung cancer and COPD unrelated to
AAT deficiency. In our current analysis, SNPs in IREB2,
LOC123688 and CHRNA3 genes were shown to be asso-
ciated with lung function phenotypes in AAT deficient
subjects (all PI ZZ) from the AAT Genetic Modifiers
Study, and suggested a potential sex-specific effect.
Replication in another cohort of AAT deficient subjects
from the UK showed that a SNP in IREB2 was also
associated with emphysema in men. This suggests that
chromosome 15q region genes that were found by
GWA studies and gene expression analysis of lung tissue
samples may also be modifier genes of COPD and
emphysema in AAT deficient subjects.
Table 2 Genetic association results between SNPs in chromosome 15 and lung function in the AAT Genetic Modifiers
Study
P-Values for Different Phenotypes
Gene SNP MAF pre-FEV1%
predicted
post-FEV1%
predicted
pre-
FEV1/FVC
post-
FEV1/FVC
IREB2 rs2568494 intron 0.30 0.02* 0.03* 0.05* 0.06
rs2656069 intron 0.22 0.48 0.29 0.59 0.46
rs1964678 intron 0.43 0.75 0.91 0.58 0.83
rs12593229 intron 0.43 0.82 0.79 0.64 0.93
rs10851906 intron 0.23 0.29 0.17 0.41 0.31
rs965604 intron 0.43 0.76 0.99 0.54 0.65
rs13180 exon 0.43 0.69 0.96 0.53 0.79
LOC123688 rs8034191 intron 0.29 0.04* 0.07 0.09 0.14
CHRNA3 rs1051730 exon 0.31 0.02* 0.03* 0.03* 0.05*
MAF = minor allele frequency
Each model was analyzed assuming an additive mode of inheritance adjusting for pack-years and pack-years2
* p ≤ 0.05
50
55
60
65
70
75
80
85
90
95
100
GG (170) GA (155) AA (33)
FE
V1
 (%
)
Genotype (number of subjects)
Figure 1 FEV1 by CHRNA3 genotype (rs1051730) in the AAT
Genetic Modifiers Study cohort. Mean values (+ SEM) for a
percent of predicted FEV1 are shown (p value = 0.02).
Figure 2 Linkage disequilibrium (LD) among SNPs analyzed in
chromosome 15. LD values are presented as r2.
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CHRNA3 was associated with lung cancer in three
separate large GWA studies. This gene was associated
with COPD by GWA and the association was replicated
in two other COPD cohorts. There have also been
recent reports of an association with smoking addiction
[27], so it is unclear whether the lung cancer and COPD
associations relate to smoking behavior, another aspect
of lung biology, or both. CHRNA3 is a subunit gene of
the nicotinic cholinergic receptor and expressed in auto-
nomic ganglia and brain but is also expressed in bron-
chial and non-bronchial epithelial cells [28]. Expression
in lung cancer cells and signal transduction and apopto-
sis studies suggests a potential role in carcinogenesis
[29]. Interestingly, there are not many observations of
lung cancer in patients with AAT deficiency, perhaps
because of mortality associated with the development of
severe COPD at an early age. Whether there is a com-
mon mechanism unrelated to smoking in the pathogen-
esis of lung cancer and COPD, or whether these
previously reported associations relate to smoking addic-
tion is unclear.
IREB2 is a protein of iron-responsive elements (IREs)
and is regulated in response to iron and oxygen supply
[30]. IREB2-/- mice have aberrant iron homeostasis and
accumulate iron in the intestine and the central nervous
system(CNS); the CNS accumulation may lead to neuro-
degenerative disease [31]. Excess iron can be toxic, but
the mechanism of neurodegenerative disease is unclear;
work is in progress to further characterize the functional
pathways impacted by IREB2 in the lung. IREB2 was
found to be differentially expressed according to lung
function by microarray experiments, and the SNPs in
IREB2 showed associations in both a COPD case-control
study and family-based studies including the Boston
Early-onset COPD and International COPD Genetics
Network studies [18]. In a recent report, IREB2 poly-
morphisms were associated with COPD susceptibility in
a European population [32]. Interestingly, rs2568494
was significantly associated with COPD in three studies
including our current study.
Previous studies of AAT deficient subjects showed
that lung function was lower in men than women [33],
and previous analyses in the AAT Genetic Modifiers
Study also showed lower lung function in men [19]. Our
current study suggests that genetic modifier effects of
IREB2 and CHRNA3 may be more prominent in males–
potentially contributing to some of the sex-specific fea-
tures of COPD susceptibility and severity among PI ZZ
subjects, although a larger sample size is needed to ver-
ify a gene-by-sex interaction.
In this study, there was no association between IREB2
and CHRNA3 genes and smoking intensity. In the AAT
Genetic Modifiers Study, results showed no association
when the cohort was stratified by smoking history (ever
smokers versus never smokers). However, there was a
marginal interaction of rs1051730 with smoking. In the
Table 3 Genetic association results between SNPs in chromosome 15 and lung function of male subgroup in the AAT
Genetic Modifiers Study cohort
P-Values for Different Phenotypes
Gene SNP pre-FEV1% predicted post-FEV1% predicted pre-
FEV1/FVC
post-
FEV1/FVC
IREB2 rs2568494 intron 0.03* 0.04* 0.07 0.03*
rs2656069 intron 0.97 0.87 0.64 0.65
rs1964678 intron 0.99 0.96 0.85 0.78
rs12593229 intron 0.95 0.93 0.87 0.76
rs10851906 intron 0.70 0.61 0.84 0.80
rs965604 intron 0.84 0.90 0.75 0.70
rs13180 exon 0.85 0.91 0.76 0.71
LOC123688 rs8034191 intron 0.04* 0.04* 0.12 0.04*
CHRNA3 rs1051730 exon 0.02* 0.02* 0.07 0.02*
Each model was analyzed assuming an additive mode of inheritance adjusting for pack-years and pack-years2
* p ≤ 0.05
Table 4 Positive findings of genetic association analysis
in the AAT Genetic Modifiers Study and the UK AATD
National Registry
AAT Genetic Modifiers
Study
UK AATD National
Registry
All subjects Association with pre- and
post- FEV1% predicted and
pre- and post- FEV1/FVC
none
Interaction
with
gender
yes yes
Interaction
with
smoking
yes only in the male subgroup
Male
subgroup
association with FEV1 and
FEV1/FVC
association with
emphysema
association with COPD
after adding smoking
interaction term
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UK study, there were significant smoking interactions of
rs2568494 and rs8034191. Smoking markedly increases
the risk of COPD and lowers the age-of-onset of COPD
in AAT deficient subjects [6,19], and despite small sam-
ple sizes, we found reasonable evidence for gene-by-
smoking interactions in the chromosome 15q region.
There are several limitations in this study. Multiple
statistical comparisons are a potential concern in any
complex disease genetics study. Adjusting for either 3
genes or 9 SNPs tested, a p value of 0.02 is marginal.
Additionally, the association with pulmonary function
did not replicate in the UK population, potentially due
to phenotypic heterogeneity between the two cohorts.
Specifically, the UK subjects have lower mean FEV1 and
potentially more emphysema, both of which could influ-
ence non-replication. Of note, the association with
emphysema was investigated only in the UK population
as chest CT scan data collection was not part of the
AAT Genetic Modifiers Study. Considering that these
SNPs (rs2568494 in IREB2, rs8034191 in LOC123688,
and rs1051730 in CHRNA3) were associated with inter-
mediate phenotypes of COPD in other populations and
that we include an independent AAT deficient replica-
tion cohort, our result are likely meaningful. Addition-
ally, this test- replication approach is even more
appealing since all subjects were homozygous recessive
for the AAT risk locus (PI ZZ). Also, replication of our
results showed association with emphysema, a less het-
erogeneous pulmonary phenotype. The associated SNPs
included two intronic (rs2568494, rs8034191) and one
synonymous exonic (rs1051730) SNP. The exonic SNP
was not associated with COPD-related phenotypes in
the UK cohort. Another limitation of our current study
is that rare functional variants in this chromosome 15
region may be contributing to the role of these genes in
COPD; genome sequencing efforts in AAT deficient
cohorts would be valuable to study rare variant associa-
tions. Functional data for associated variants are cur-
rently lacking, but many groups are pursuing functional
work on this chromosome 15 region.
Conclusion
We have identified that the chromosome 15q25 region
likely contains at least one potential modifier gene of
COPD phenotypes in individuals with severe AAT defi-
ciency. The association may be due to smoking beha-
vior, but this is less likely; additionally, these
associations may have sex-specific effects. Future direc-
tions will include further evaluation of the gene-by-sex
interaction in larger cohort with AAT deficiency and
identification of the functional variant or variants in this
region.
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